Article Text

other Versions

Decreased CSF amyloid beta (1-40) levels in frontotemporal lobar degeneration
  1. YAL Pijnenburg (y.pijnenburg{at}
  1. VUMC, Netherlands
    1. SNM Schoonenboom (niki.schoonenboom{at}
    1. VUMC, Netherlands
      1. PD Mehta
      1. Institute for basic reasearch in developmental disabilities, United States
        1. SP Mehta
        1. Institute for basic reasearch in developmental disorders, United States
          1. C Mulder (c.mulder{at}
          1. Clinical Chemistry, VUMC, Netherlands
            1. R Veerhuis (r.veerhuis{at}
            1. Vrije Universiteit medical center, Netherlands
              1. MA Blankenstein (ma.blankenstein{at}
              1. VU Medisch Centrum, Netherlands
                1. P Scheltens (p.scheltens{at}
                1. VU medical Center, Netherlands


                  The role of amyloid metabolism in the pathophysiology of FTLD remains to be elucidated. We compared CSF levels of amyloid beta 1-40 (Aβ40) and amyloid beta 1-42 (Aβ42) in patients with frontotemporal lobar degeneration (FTLD, n=21) versus patients with Alzheimer’s disease (AD, n=39) and control subjects (n=30). While in AD cases Aβ42 levels were lower and CSF Aβ40 levels equal to those in controls, a significant decrease in Aβ40 and increase in CSF Aβ42/Aβ40 ratio was observed in FTLD compared AD and control subjects. These findings favour a differential involvement of amyloid β peptides in FTLD compared to AD.

                  • Alzheimer's disease
                  • Cerebrospinal fluid
                  • amyloid beta
                  • biomarker
                  • frontotemporal lobar degeneration

                  Statistics from

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.